TrialNeuro-oncology2015

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

James Schuster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.